Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: An Egyptian study
Tài liệu tham khảo
Go, 2004, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N Engl J Med, 351, 1296, 10.1056/NEJMoa041031
Dogra, 2006, Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD, Am J Kidney Dis, 48, 926, 10.1053/j.ajkd.2006.08.008
Stam, 2006, Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study, J Am Soc Nephrol, 17, 537, 10.1681/ASN.2005080834
Endemann, 2004, Endothelial dysfunction, J Am Soc Nephrol, 15, 1983, 10.1097/01.ASN.0000132474.50966.DA
Chudek, 2006, The adipose tissue as an endocrine organ — a nephrologists' perspective, Contrib Nephrol, 151, 70, 10.1159/000095320
Axelsson, 2008, Role of fat mass and adipokines in chronic kidney disease, Curr Opin Nephrol Hypertens, 17, 25, 10.1097/MNH.0b013e3282f2905f
Axelsson, 2008, Obesity in chronic kidney disease: good or bad?, Blood Purif, 26, 23, 10.1159/000110559
Axelsson, 2006, Adipose tissue and inflammation in chronic kidney disease, Contrib Nephrol, 151, 165, 10.1159/000095327
Fukuhara, 2005, Visfatin: a protein secreted by visceral fat that mimics the effects of insulin, Science, 307, 426, 10.1126/science.1097243
Song, 2008, Visfatin: a new player in mesangial cell physiology and diabetic nephropathy, Am J Physiol Renal Physiol, 295, F1485, 10.1152/ajprenal.90231.2008
Takebayashi, 2007, Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus, Metabolism, 56, 451, 10.1016/j.metabol.2006.12.001
Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group, Ann Intern Med, 130, 461, 10.7326/0003-4819-130-6-199903160-00002
Nusken, 2007, Preanalytical influences on the measurement of visfatin by enzyme immuno assay, Clin Chim Acta, 382, 154, 10.1016/j.cca.2007.04.004
Rifai, 1999, Clinical efficacy of an automated high-sensitivity C-reactive protein assay, Clin Chem, 45, 2136, 10.1093/clinchem/45.12.2136
Ida, 1989, Establishment of strongly neutralizing monoclonal antibody to human interleukin-6 and its epitope analysis, Biochem Biophys Res Commun, 165, 728, 10.1016/S0006-291X(89)80027-0
Corretti, 2002, Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force, J Am Coll Cardiol, 39, 257, 10.1016/S0735-1097(01)01746-6
Pignoli, 1986, Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging, Circulation, 74, 1399, 10.1161/01.CIR.74.6.1399
Howard, 1993, Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators, Stroke, 24, 1297, 10.1161/01.STR.24.9.1297
Sarnak, 2003, Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention, Circulation, 108, 2154, 10.1161/01.CIR.0000095676.90936.80
Pecoits-Filho, 2003, Associations between circulating inflammatory markers and residual renal function in CRF patients, Am J Kidney Dis, 41, 1212, 10.1016/S0272-6386(03)00353-6
Axelsson, 2007, Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD, Am J Kidney Dis, 49, 237, 10.1053/j.ajkd.2006.11.021
Malyszko, 2008, Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure, Adv Med Sci, 53, 32, 10.2478/v10039-008-0024-x
Stenvinkel, 2000, Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease, Nephrol Dial Transplant, 15, 1624, 10.1093/ndt/15.10.1624
Yilmaz, 2008, Serum visfatin concentration and endothelial dysfunction in chronic kidney disease, Nephrol Dial Transplant, 23, 959, 10.1093/ndt/gfm727
Yilmaz, 2009, Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?, Clin Transplant, 23, 241, 10.1111/j.1399-0012.2008.00921.x
Joannides, 1995, Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo, Circulation, 91, 1314, 10.1161/01.CIR.91.5.1314
van der Veer, 2007, Extension of human cell lifespan by nicotinamide phosphoribosyltransferase, J Biol Chem, 282, 10,841, 10.1074/jbc.C700018200
Malyszko, 2009, Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients, Transplant Proc, 41, 150, 10.1016/j.transproceed.2008.10.086
Kato, 2009, Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients, Am J Nephrol, 29, 31, 10.1159/000148648
Oki, 2007, Circulating visfatin level is correlated with inflammation, but not with insulin resistance, Clin Endocrinol (Oxford), 67, 796, 10.1111/j.1365-2265.2007.02966.x
Moschen, 2007, Visfatin, an adipocytokine with proinflammatory and immunomodulating properties, J Immunol, 178, 1748, 10.4049/jimmunol.178.3.1748
Brentano, 2007, Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities, Arthritis Rheum, 56, 2829, 10.1002/art.22833
Dahl, 2007, Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization, Circulation, 115, 972, 10.1161/CIRCULATIONAHA.106.665893